Sight Sciences (NASDAQ:SGHT) Issues Quarterly Earnings Results

Sight Sciences (NASDAQ:SGHT) released its quarterly earnings results on Wednesday. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12), FiscalAI reports. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%. The company had revenue of $24.92 million for the quarter, compared to analyst estimates of $23.55 million.

Here are the key takeaways from Sight Sciences’ conference call:

• Sight Sciences reported record third-quarter revenue of $24.9 million, up 25% year over year, and raised 2026 revenue guidance to $92 million–$93 million, implying about 20% growth. Adjusted operating expense guidance was maintained at $92 million–$94 million.
• IDE revenue reached a record $3.9 million, up 45% sequentially, prompting the company to raise its full-year IDE outlook to approximately $12 million. Ordering accounts and utilization both increased, though TearCare growth remains concentrated in a limited reimbursed footprint and broader payer access is not yet assured.
• IG revenue grew 7% to $21 million, with active accounts at a record high; full-year IG guidance was raised to $80 million–$81 million. The company launched its next-generation OMNI Ultra in the U.S. and said expanded Aetna coverage adds about 25 million covered lives.
• Cash used in the quarter fell to $2.4 million from $9.1 million a year earlier, while year-to-date cash use improved 48%; the company ended the quarter with $77.4 million in cash. Management said it remains focused on cash-flow breakeven and extended the debt interest-only period through August 2027.

Sight Sciences Price Performance

SGHT traded up $0.08 during trading on Thursday, hitting $9.76. The company’s stock had a trading volume of 388,499 shares, compared to its average volume of 275,184. The company has a quick ratio of 4.67, a current ratio of 4.95 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $537.62 million, a price-to-earnings ratio of -17.41 and a beta of 2.44. The firm’s 50 day moving average price is $8.66 and its two-hundred day moving average price is $6.05. Sight Sciences has a 12 month low of $3.38 and a 12 month high of $10.14.

More Sight Sciences News

Here are the key news stories impacting Sight Sciences this week:

• Positive Sentiment: Higher revenue outlook: Sight Sciences raised its 2026 revenue guidance to $92–$93 million and indicated a higher target of about $12 million for IDE. The updated outlook signals confidence in growth. Article: Sight Sciences signals 2026 revenue outlook
• Positive Sentiment: Q3 revenue topped estimates: Revenue was $24.92 million, above analysts’ $23.55 million estimate. The quarterly loss of $0.12 per share matched expectations and narrowed from $0.16 a year earlier. Article: Sight Sciences Q3 2026 financial results
• Positive Sentiment: CMS code for TearCare: CMS established a direct practice expense supply code for TearCare’s single-use SmartLids component. This may improve payment recognition and help support use of the product, though the announcement does not specify a payment rate. Article: CMS establishes a TearCare SmartLids supply code
• Negative Sentiment: Profitability remains a concern: SGHT still reported a quarterly loss, so investors will look for revenue growth to translate into improved margins and a path toward profitability.

Wall Street Analyst Weigh In

A number of research firms have weighed in on SGHT. HC Wainwright initiated coverage on shares of Sight Sciences in a research report on Thursday, October 15th. They set a “buy” rating and a $14.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price target (up from $9.00) on shares of Sight Sciences in a research report on Thursday. Citigroup lifted their price objective on Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Wall Street Zen raised Sight Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research note on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.62.

Insiders Place Their Bets

In other Sight Sciences news, CTO David Badawi sold 7,797 shares of the stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $70,562.85. Following the sale, the chief technology officer owned 1,975,075 shares of the company’s stock, valued at $17,874,428.75. This represents a 0.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Badawi sold 29,653 shares of the firm’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $9.05, for a total transaction of $268,359.65. Following the completion of the sale, the chief executive officer owned 6,092,819 shares of the company’s stock, valued at $55,140,011.95. The trade was a 0.48% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 47,646 shares of company stock worth $429,157 over the last ninety days. Company insiders own 30.40% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.